Genmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?

Key Points

• Genmab A/S shares opened at $31.50, down from a previous close of $33.17, indicating a significant gap down in price.
• Analyst ratings show mixed sentiments; Zacks upgraded the stock to a "strong-buy," while Wall Street Zen downgraded it to a "buy," resulting in a consensus rating of "Moderate Buy" and an average target price of $40.80.
• The company reported $0.54 EPS in its latest earnings, surpassing consensus expectations, and has set FY 2025 guidance with a forecast of 1.45 EPS for the current fiscal year.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $33.17, but opened at $31.50. Genmab A/S shares last traded at $31.04, with a volume of 1,083,330 shares.

Analyst Ratings Changes

A number of research analysts have commented on GMAB shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Genmab A/S in a report on Wednesday, October 8th. Zacks Research raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd. Wall Street Zen downgraded Genmab A/S from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Truist Financial boosted their price objective on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Finally, Guggenheim upgraded Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.80.

Genmab A/S Trading Down 7.9%

The company has a 50 day moving average of $27.95 and a 200 day moving average of $23.39. The firm has a market cap of $19.62 billion, a price-to-earnings ratio of 15.36, a P/E/G ratio of 1.85 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors have recently bought and sold shares of GMAB. Headlands Technologies LLC boosted its position in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after purchasing an additional 1,464 shares in the last quarter. Osaic Holdings Inc. increased its stake in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock worth $33,000 after purchasing an additional 440 shares during the last quarter. CWM LLC increased its stake in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company's stock worth $37,000 after purchasing an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after purchasing an additional 1,070 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company's stock worth $44,000 after purchasing an additional 1,174 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.